中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Viral Diseases
NASH/PBC
Cancer
Exploratory Indications
Products&Pipeline
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Ascletis Accredited as “One of China’s Top Ten Innovative Companies in 2019”
2019-12-07
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
2019-11-29
Ascletis to Present at the 17th Annual Morgan Stanley Asia Pacific Summit
2019-11-26
Dr. Jinzi Wu was Selected as the 10th Science and Technology New Zhejiang Merchants
2019-11-08
Manuscript Publication of the First All-oral DAA HCV Regimen Developed by Ascletis from China in the Journal of Clinical and Translational Hepatology
2019-10-21
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
2019-10-08
Dr. Jinzi J. Wu to Attend The Fortune Global Sustainability Forum 2019
2019-09-04
Ascletis Received IND Approval for its NASH Drug
2019-08-28
Ascletis Opens Clinical Development Shanghai Center
2019-08-12
Ascletis’ Strategic Partner 3-V Biosciences Announced its Name Change and Financing Status
2019-08-06
1
2
3
»